Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO | Hyderabad News
Hyderabad: Granules India Ltd has drawn up plans to invest about ₹2,000 crore over the next three to four years as part of a broader strategy to build a more differentiated and higher-margin pharmaceuticals business focused on differentiated products, peptide CDMO, oncology and wider global market access.The organic capital expenditure will be directed toward complex…
